RBC Europe’s Takeda Pharmaceutical TAK Stock Holding History

RBC Europe’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$14K	Buy	1,027 +395	+63%	+$5.64K	﹤0.01%	466
2022 Q1	$9K	Sell	632 -152	-19%	-$2.23K	﹤0.01%	540
2021 Q4	$11K	Buy	784 +281	+56%	+$3.94K	﹤0.01%	522
2021 Q3	$8.24K	Hold	503	–	–	﹤0.01%	972
2021 Q2	$8.46K	Sell	503 -493	-49%	-$8.39K	﹤0.01%	986
2021 Q1	$18.2K	Sell	996 -189	-16%	-$3.4K	﹤0.01%	795
2020 Q4	$21.6K	Hold	1,185	–	–	﹤0.01%	697
2020 Q3	$21.1K	Hold	1,185	–	–	﹤0.01%	638
2020 Q2	$21.2K	Buy	1,185 +189	+19%	+$3.39K	﹤0.01%	617
2020 Q1	$15.1K	Sell	996 -781	-44%	-$14.2K	﹤0.01%	606
2019 Q4	$35.1K	Buy	1,777 +369	+26%	+$7.06K	﹤0.01%	532
2019 Q3	$24.2K	Hold	1,408	–	–	﹤0.01%	590
2019 Q2	$24.9K	Buy	1,408 +412	+41%	+$7.5K	﹤0.01%	605
2019 Q1	$20.3K	Buy	+996	New	+$20K	﹤0.01%	644

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RBC Europe's TAK Position: Q2 2022 in Review

RBC Europe increased its Takeda Pharmaceutical (TAK) stake by 63% in Q2 2022, buying an estimated $5.64K and bringing the position to 1,027 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

RBC Europe first reported a position in TAK in Q1 2019 and has held it in 14 quarters since. The position peaked at $35.1K in Q4 2019. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

RBC Europe held 1,027 shares of Takeda Pharmaceutical worth $14K as of Q2 2022.
RBC Europe bought 395 Takeda Pharmaceutical shares in Q2 2022, an estimated $5.64K.
Takeda Pharmaceutical made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #466 holding.
RBC Europe first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 14 quarters since.
RBC Europe's Takeda Pharmaceutical position peaked at $35.1K in Q4 2019.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.